Inhibitors of ABL and the ABL-T315I mutation
G Noronha, J Cao, CP Chow… - Current topics in …, 2008 - ingentaconnect.com
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder caused by
increased and unregulated growth of myeloid cells in the bone marrow, and the …
increased and unregulated growth of myeloid cells in the bone marrow, and the …
Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC …
M Talpaz, H Kantarjian, NP Shah, N Donato, J Nicoll… - 2004 - ashpublications.org
BMS-354825 is a novel, orally available, dual SRC/ABL kinase inhibitor with 100-fold
greater potency to inhibit BCR-ABL in vitro than imatinib and has in vitro and in vivo …
greater potency to inhibit BCR-ABL in vitro than imatinib and has in vitro and in vivo …
Resistance to targeted therapy in chronic myelogenous leukemia
A Hochhaus, P Erben, T Ernst, MC Mueller - Seminars in hematology, 2007 - Elsevier
The advent of the Bcr-Abl selective tyrosine kinase inhibitor imatinib mesylate (Glivec,
Gleevec, Novartis, East Hanover, NJ) has substantially changed the treatment landscape for …
Gleevec, Novartis, East Hanover, NJ) has substantially changed the treatment landscape for …
BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone …
ME Gorre, K Ellwood-Yen, G Chiosis… - Blood, The Journal …, 2002 - ashpublications.org
Clinical resistance to imatinib mesylate is commonly observed in patients with advanced
Philadelphia chromosome–positive (Ph+) leukemias. Acquired resistance is typically …
Philadelphia chromosome–positive (Ph+) leukemias. Acquired resistance is typically …
The BCR-ABL story: bench to bedside and back
S Wong, ON Witte - Annu. Rev. Immunol., 2004 - annualreviews.org
The twenty-first century is beginning with a sharp turn in the field of cancer therapy.
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …
The interface between BCR‐ABL‐dependent and‐independent resistance signaling pathways in chronic myeloid leukemia
G Nestal de Moraes, PS Souza… - Leukemia research …, 2012 - Wiley Online Library
Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder characterized by the
presence of the Philadelphia chromosome which resulted from the reciprocal translocation …
presence of the Philadelphia chromosome which resulted from the reciprocal translocation …
A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia
Resistance to the BCR-ABL inhibitor imatinib mesylate (IM) poses a major problem for the
treatment of chronic myeloid leukemia (CML). IM resistance often results from a secondary …
treatment of chronic myeloid leukemia (CML). IM resistance often results from a secondary …
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations
Rare cases of chronic myelogenous leukemia (CML) express high levels of alternatively
spliced BCR-ABL mRNA with a 35-bp insertion (35INS) between ABL kinase domain exons …
spliced BCR-ABL mRNA with a 35-bp insertion (35INS) between ABL kinase domain exons …
Choosing the best second‐line tyrosine kinase inhibitor in imatinib‐resistant chronic myeloid leukemia patients harboring Bcr‐Abl kinase domain mutations: How …
S Soverini, G Rosti, I Iacobucci, M Baccarani… - The …, 2011 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the IC50 of a tyrosine kinase inhibitor and the kind of information this parameter provides …
the IC50 of a tyrosine kinase inhibitor and the kind of information this parameter provides …
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
T Maekawa, E Ashihara, S Kimura - International journal of clinical …, 2007 - Springer
Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a
single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and …
single, acquired genetic abnormality. Identification of the Bcr-Abl kinase fusion protein and …